NCT00687453

Insulin Glargine Versus Twice-Daily NPH

The Utility of Insulin Glargine (Lantus) Compared to NPH in Ethnic Minority Type 2 Diabetic Subjects on Combination Insulin-Oral Agent Therapy

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Charles Drew University of Medicine and Science · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To compare the efficacy and safety of once-nightly insulin glargine versus twice-daily NPH insulin in ethnic minority type 2 diabetic patients inadequately treated with once-nightly NPH insulin alone.

Detailed description

Insulin glargine has a longer action than compared to NPH insulin, but whether this results in improved control when compared to twice-daily NPH insulin is not known when used in low-income ethnic minority patients. This study investigates whether insulin glargine may be more or less effective and safe than twice-daily NPH insulin in this population.

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	Insulin glargine at bedtime instead of NPH	Insulin glargine at bedtime substituting for NPH insulin at bedtime
DRUG	NPH twice-daily	Addition of morning NPH to bedtime NPH

Timeline

• Start date: 2003-02-01
• Primary completion: 2009-08-01
• Completion: 2009-08-01
• First posted: 2008-05-30
• Last updated: 2023-11-02
• Results posted: 2010-10-07

Locations

1 site across 1 country: United States